Lucas Antonio on Redefining Tumor Treatment with Fluxus

Lucas Antonio Diez Martínez is the CEO and founder of Avamed Synergy, a deep-tech company based in Alicante, Spain, specializing in technological innovations for precision medicine. Under his leadership, the company has developed groundbreaking projects such as Fluxus, a platform that uses AI and 3D imaging to optimize oncological diagnosis and treatment. Avamed Synergy has achieved significant milestones, including securing €800,000 in initial investment funding, positioning it as a leader in personalized medical solutions.

Lucas has been instrumental in steering the company towards pioneering advancements, including collaborations on innovative medical devices like a 3D bionic scaphoid. This initiative, in partnership with renowned specialists, has made notable contributions to orthopedic surgery by improving patient outcomes and drawing national recognition. In an interview, Lucas speaks on how he has integrated advanced technologies into healthcare, and how through strategic collaborations and research efforts, he has been able to drive the evolution of personalized and precision medicine across Europe​.

Excerpts from an interview:

Founding of Avamed Synergy

The company is dedicated to empowering medical professionals to provide accurate diagnoses and personalized treatments. Predictive oncology and associated surgical care face immense challenges and uncertainties, particularly in anticipating tumor behavior and preparing for complex treatments. For patients, these obstacles are compounded by the emotional and physical toll of invasive procedures, which do not always produce the desired results. Recognizing these challenges, the company developed Fluxus, an innovative tool designed to predict the progression and dynamics of tumors and quantify uncertainties in their treatment. “By providing advanced information about tumor evolution, Fluxus minimizes the risks of complications both during treatment and during surgery. “This leads to better outcomes, fewer unwanted impacts and a more efficient approach to care, offering significant benefits to both patients and healthcare providers,” says Lucas.

Avamed Synergy’s comprehensive platform – Key features

Avamed Synergy’s Fluxus environment is the world’s first predictive model with an AI-assisted tumor-host spatial localization interface. Fluxus allows the clinical team to follow the disease very closely, from diagnosis to its evolution, observing the tumor at all times and analyzing possible changes or modifications. We cannot forget that what ultimately kills the cancer patient is the resistance of the cells to the treatment. It will mean a radical paradigm shift given the option of monitoring how injuries and tissues change thanks to Fluxus.

“Fluxus uniquely combines uncertainty quantification with multiscale data, enabling accurate modeling of tumor evolution and optimized oncological decision-making through a 3D tumor-host interface,” adds Lucas. This tool’s advanced AI generates a 3D digital hybrid twin from the medical image, visualizing how a tumor could evolve and impact surrounding structures, such as organs, tissues and bones. This predictive ability allows doctors to make more accurate and informed decisions before surgery.

The standout feature of the FLUXUS platform is its predictive model, which differentiates it from other solutions on the market. It goes beyond simply visualizing the tumor and anticipating its behavior within the host environment. This transformative approach significantly improves treatment strategies and surgical planning, offering a new standard in oncology care. By integrating cutting-edge visualization with predictive analytics, Fluxus revolutionizes the way physicians approach tumor management and patient outcomes.

Leadership traits

Being results-oriented ensures focused efforts toward clear objectives, maintaining high productivity and efficiency. Noted Lucas that, effective communication is vital. It allows leaders to articulate ideas and inspire their teams while fostering collaboration. “Entrepreneurs also benefit from being calculated risk-takers, balancing bold decisions with strategic evaluation to mitigate potential downsides.” Persistence is key to overcoming obstacles, while empathy strengthens relationships by valuing diverse perspectives. High ethical standards build trust and credibility, both within teams and with external stakeholders.

The success mantras

For business leaders, overcoming the fear of failure requires strategic mindset shifts and actionable steps, warns Lucas. “Viewing failure as a learning opportunity is critical; mistakes offer valuable insights that inform future decisions. Setting realistic, achievable goals and breaking them into smaller steps can make daunting challenges more manageable, fostering a sense of progress.”

Healthcare Startups: Innovation Meets Regulation

Healthcare startups face several critical challenges. Navigating strict regulations and compliance is essential to avoid legal issues, while ensuring robust data security safeguards patient privacy. Establishing financing and sustainability can be difficult, requiring a solid financial plan and sector-savvy investors. Bridging access and equity gaps, particularly for underserved areas, remains a persistent issue.

Adopting new technologies often encounters resistance from patients and professionals, necessitating proper training. Maintaining quality of care is vital, ensuring technology enhances rather than hinders the doctor-patient relationship. Startups must embrace continuous innovation to remain competitive in a rapidly evolving industry and implement effective change management strategies to minimize disruptions. Addressing these challenges proactively can help healthcare startups establish themselves and grow sustainably.

Healthcare industry- Challenges galore

The rapid expansion of healthcare technology during the pandemic has brought significant benefits but also presents challenges that must be addressed in the post-pandemic world. One key concern is information security; the rise in digital healthcare increases the need for robust cybersecurity to protect patient data from breaches and ensure privacy. According to Lucas, yet another challenge is the digital divide, where unequal access to technology prevents many patients from benefiting from telemedicine and digital services, necessitating efforts to bridge this gap.

Adoption of new technologies can face resistance from patients and healthcare professionals, highlighting the need for training and support to ease the transition and foster comfort with these tools. Additionally, while technology can reduce administrative burdens, improper implementation may lead to work overload, underscoring the importance of designing systems that truly streamline healthcare workflows.

Maintaining the quality of care is another priority, ensuring technological efficiency does not compromise personalized attention. Furthermore, accelerating bureaucratization and automation of administrative processes can free healthcare professionals to focus more on patient care.

Addressing these challenges is essential to harness healthcare technology’s potential while safeguarding equitable, secure, and high-quality care. A thoughtful approach will enable the healthcare sector to maximize the opportunities of digital transformation in the post-pandemic era.

Avamed Synergy- The road ahead

Lucas concludes that Fluxus has achieved a functional minimum viable product (MVP) capable of generating highly realistic three-dimensional images, with plans to integrate native AI algorithms. “The project is set for a European presentation by the end of the year and aims for market launch in 2025. Alongside Fluxus, advancements in personalized medicine include the creation of a 3D bionic scaphoid in collaboration with Dr. Luis Aguilella, a renowned orthopedic surgeon.” This breakthrough avoids arthrodesis, restoring natural mobility for patients with scapholunate pathology and has garnered national attention.

The team is actively collaborating with biohealth institutions like IMIB, IBIMA, SACYL Innova, ISABIAL, and INCLIVA to expand clinical research and sector knowledge, ensuring continued innovation and impact in precision medicine.